---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000101"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-09-02T23:59:59+00:00"
generated_at: "2026-06-23T17:07:07.608163+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis files second patent infringement suit against Teva over generic CABOMETYX

## Summary
- Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.
- Teva filed ANDA with Paragraph IV certification; Exelixis seeks injunction and FDA approval delay until patent expires Feb 10, 2032.
- This is the second case; first case (2021) is stayed administratively, asserting three other patents expiring July 9, 2033.
- No trial scheduled yet; Exelixis seeks equitable relief to block Teva's generic launch before patent expiration.

## SEC filing metadata
- accession: 0000939767-22-000101
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-09-02T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/0000939767-22-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/exel-20220902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000101
- JSON: https://secwatch.observer/filing/0000939767-22-000101.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.